Want to see GHRS full AI Analyst Report?
Top Page
GH Research
(NASDAQ:GHRS)
Select Model
Select Model
Rating:53Neutral
Price Target:
$29.00
▲(58.12% Upside)
Action:Reiterated
Date:06/27/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn), partially offset by a strong, low-debt balance sheet. Technicals are a meaningful positive with a clear uptrend, though overbought indicators add near-term risk. Valuation is constrained by negative earnings and no dividend support.
Positive Factors
Strong balance sheet, low leverage
Very low debt and substantial equity provide a durable financial cushion that supports continued R&D and clinical programs without immediate refinancing. This strengthens negotiating leverage for partnerships and gives the company structural runway to advance trials absent product revenue.
Negative Factors
No revenue; widening net losses
Persistent lack of product revenue and widening losses reflect a development-stage profile that will continue to consume capital until commercialization. Over months this raises execution and funding risk and constrains reinvestment capacity without external financing or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet, low leverage
Very low debt and substantial equity provide a durable financial cushion that supports continued R&D and clinical programs without immediate refinancing. This strengthens negotiating leverage for partnerships and gives the company structural runway to advance trials absent product revenue.
Read all positive factors
GH Research (GHRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.81B
Dividend YieldN/A
Average Volume (3M)245.16K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth-15.44%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.92
Shares Outstanding68,557,175
10 Day Avg. Volume254,669
30 Day Avg. Volume245,164
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.56K
Enterprise Value/Ebitda-22.30
Forecast
1Y Price Target
$41.67Price Target Upside127.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
GH Research Business Overview & Revenue Model
Company Description
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments,...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, GH Research does not have publicly disclosed recurring revenue from product sales. The company’s operations are primarily funded through external financing, including proceeds from equity offerings (s...
GH Research Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -350.00K | -335.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -55.86M | -47.46M | -38.60M | -35.21M | -22.41M | -9.17M |
| Net Income | -56.41M | -48.26M | -38.96M | -35.59M | -22.46M | -9.20M |
Balance Sheet | ||||||
| Total Assets | 275.27M | 288.23M | 188.27M | 226.30M | 254.36M | 279.92M |
| Cash, Cash Equivalents and Short-Term Investments | 267.32M | 280.71M | 149.32M | 161.56M | 165.96M | 276.78M |
| Total Debt | 432.00K | 512.00K | 624.00K | 974.00K | 0.00 | 0.00 |
| Total Liabilities | 11.89M | 8.53M | 9.32M | 7.33M | 4.55M | 2.75M |
| Stockholders Equity | 263.38M | 279.70M | 178.95M | 218.97M | 249.82M | 277.18M |
Cash Flow | ||||||
| Free Cash Flow | -46.51M | -43.67M | -42.33M | -33.44M | -26.27M | -15.39M |
| Operating Cash Flow | -46.33M | -43.55M | -42.28M | -33.34M | -26.20M | -15.28M |
| Investing Cash Flow | 43.35M | 46.17M | 65.14M | -54.10M | -84.69M | -104.00K |
| Financing Cash Flow | -2.23M | 139.65M | -304.00K | -204.00K | 0.00 | 286.45M |
GH Research Technical Analysis
Positive
18.34
Price Trends
22.16
Positive
18.76
Positive
16.46
Positive
Market Momentum
1.47
Negative
63.08
Neutral
79.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GHRS, the sentiment is Positive. The current price of 18.34 is below the 20-day moving average (MA) of 23.08, below the 50-day MA of 22.16, and above the 200-day MA of 16.46, indicating a bullish trend. The MACD of 1.47 indicates Negative momentum. The RSI at 63.08 is Neutral, neither overbought nor oversold. The STOCH value of 79.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GHRS.
GH Research Risk Analysis
GH Research disclosed 104 risk factors in its most recent earnings report. GH Research reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GH Research Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $2.13B | -17.37 | -56.07% | ― | 3.42% | -11.04% | |
56 Neutral | $963.97M | 69.94 | 4.75% | ― | 15.66% | ― | |
53 Neutral | $1.81B | -28.72 | -19.83% | ― | ― | -15.44% | |
52 Neutral | $3.87B | -11.31 | -43.94% | ― | 39.04% | 29.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $990.72M | -3.83 | -161.87% | ― | ― | -6.15% | |
45 Neutral | $583.39M | ― | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
GHRS
GH Research
26.42
11.39
75.78%
RLAY
Relay Therapeutics
17.76
14.16
393.33%
TSHA
Taysha Gene Therapies
6.65
4.22
173.66%
SANA
Sana Biotechnology
3.56
0.64
21.92%
PHAR
Pharming Group
13.66
3.00
28.22%
PRME
Prime Medicine, Inc.
3.89
0.82
26.71%
GH Research Corporate Events
GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM
Jun 26, 2026
On June 25, 2026, GH Research PLC held its annual general meeting, where shareholders approved all board-recommended resolutions, including the re-election of directors Florian Schönharting, Michael Forer, Dermot Hanley and Duncan Moore. The ...
GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001
Jun 4, 2026
On June 4, 2026, GH Research PLC reported full Phase 2a results for its inhaled mebufotenin candidate GH001 in postpartum depression, showing a mean MADRS reduction of 35.4 points by Day 8 and remission in all 10 patients within two hours of dosin...
GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026
May 21, 2026
GH Research PLC will showcase new Phase 2b data on its inhaled psychedelic-based depression therapy GH001 at the American Society of Clinical Psychopharmacology annual meeting in Miami from May 26–29, 2026. The presentations underline the co...
GH Research Launches $200 Million At-the-Market Share Offering With Stifel
May 14, 2026
On May 14, 2026, GH Research PLC entered into an at-the-market equity offering sales agreement with Stifel, Nicolaus Company to sell up to $200 million of its ordinary shares from time to time. The shares are registered under an existing Form F-3...
GH Research Posts Wider Q1 2026 Loss as R&D and Admin Costs Rise
May 14, 2026
On May 14, 2026, GH Research PLC filed a Form 6-K in the United States reporting its first-quarter 2026 results and providing business updates, alongside posting an updated investor presentation. The filing also furnished unaudited condensed conso...
GH Research Sets June 25, 2026 AGM and Tables Board, Auditor Votes
May 13, 2026
GH Research has called its 2026 annual general meeting for June 25, 2026, in Dublin, inviting shareholders of record as of May 1, 2026 to attend, vote and review the company’s 2025 Irish statutory financial statements. The company has circul...
GH Research to Attend APA Annual Meeting in San Francisco in May 2026
May 13, 2026
GH Research PLC announced on May 13, 2026, that it will attend the American Psychiatric Association Annual Meeting in San Francisco, California. The conference is scheduled to take place from May 16 to May 20, 2026, and the company’s partici...
GH Research Raises $111 Million in Completed Share Offering to Fund Depression Pipeline
Apr 30, 2026
On April 30, 2026, GH Research PLC completed an underwritten public offering of 6,527,779 ordinary shares at $18.00 per share, raising estimated net proceeds of about $111.2 million after fees. The transaction, priced a day earlier and led by Stif...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.